Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2006

Integrated BioPharma’s Revenues Increased 77% over the Last Fiscal Year

  • Integrated BioPharma reported financial results for fiscal year ended June 30, 2006. Revenues increased by approximatly 77%, or $25.1 million, from the end of fiscal year 2005 to $57.8 million. The company attributes this sales increase to enhanced sales of its branded nutraceutical products. Gross profits were $21,840,661 compared to $1,991,966 for fiscal 2005.

    “We believe the results for fiscal 2006 speak for themselves and provide a strong validation of our strategic plan to continue building the company’s nutraceutical business,” says E. Gerald Kay, CEO.

    Operating income for fiscal 2006 increased by $16.2 million to $5.1 million compared to an operating loss of $11.1 million for the fiscal year ended June 30, 2005. Net income applicable to common shareholders for the same period was $5.5 million, or $0.34 per diluted share, compared with a net loss applicable to common shareholders of $11.4 million, or $0.90 per diluted share, for fiscal 2005, which included nonrecurring income of $2.5 million relating to settlement of a lawsuit.

    Net income loss applicable to common shareholders is calculated after cash preferred stock dividends of $482,463 and noncash preferred stock deemed dividends of $2,399,643 for the 2006 fiscal year.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »